DENVER, CO / ACCESSWIRE / November 26, 2018 / Nexien BioPharma, Inc. (OTCQB: NXEN) (”Nexien” or the ”Company”) is a US-based pharmaceutical company focused on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. CEO, Alex Wasyl, joined Stock Day’s Everett Jolly for the first time to discuss the recent acquisition of CRX Bio-Holdings by Nexien BioPharma, and the Company’s future in the pharmaceutical industry.

Jolly began the interview by asking Wasyl to provide some background information about the Company. Wasyl explained that Nexien BioPharma is the new name of a company that recently acquired CRX Bio-Holdings. He added, “We had a lot of synergies and synchronicities in management and intellectual property that led to the acquisition.” He also explained that Nexien is a traditionally constructed pharmaceutical company in the United States, operating under full FDA compliance. Wasyl also noted that his background is in the life sciences sectors.

Jolly inquired about the Company’s progress on being listed on the CSE. Wasyl explained, “We are in the application process, and we have just filed a Restated and Amended Application, and we are very confident that we will be listed in due course and hopefully in the near future.” And stated, “The listing on the CSE is not a funding event, but rather a stepping stone to a platform that we can use to continue our research and have greater capital access due to the more favorable investment environment in Canada.”

Wasyl mentioned that it was also important to note that they are not currently trading a lot of volume and recently the significant number of shares of stock for the Company went from restricted to free-float, so there is naturally some volatility in the stock. Wasyl continued, “Any near-term fundraising events will be mostly private placement.”

After noting the importance of an experienced management team, Jolly asked Wasyl to elaborate on the senior management staff of the Company. Wasyl responded, “There’s a major synergy between former CRX Bio and now Nexien BioPharma as a collective. We were able to broaden the team’s span of experience all the way from Wall Street down to bio-engineering and nano-materials.” He continued by adding that the team has experts across several areas including cannabinoid science and research, pre-clinical research program development, intellectual property, and regulatory affairs, and more. Overall, Wasyl stated, “We are really happy about having such a comprehensive and dynamic team.”

More information on the management team behind the Company can be found directly on their website, or by clicking on this link: https://www.nexienbiopharma.com/team.

Wasyl then expanded on the goals of the Company and shared, “The ultimate goal is not only to provide shareholder value but to get these therapeutics that are much demanded to patients in need.” He continued, “We intend to be a leader in this space.”

Jolly asked, “Do you believe we are soon to approach a paradigm shift in pharmaceuticals as we know it?”

Wasyl provided insight and explained, “I do. I think that the interest in medical marijuana has led to a divergence in that sort of advocacy, where now the biotechnology and pharmaceutical industry is taking an interest in the evidence and potential of cannabinoids and advanced cannabinoid pharmaceutical formulations.” He continued and added, “It is becoming increasingly more accepted in academia and by the pharmaceutical industry that there is untapped therapeutic value and benefits for patients in this therapeutic class.”

At the close of the interview, Jolly asked Wasyl what the vision is for the next 16-18 months of the Company. Wasyl replied, “We hope to be a leader in the cannabinoid pharmaceutical space. We are a true pharmaceutical company, not a cannabis company. We are publicly listed, and look forward to collaborating with other companies in this space.” Wasyl also shared his excitement about upcoming research programs and partnerships that they are preparing to announce.

To learn more about Nexien BioPharma Inc., listen to the full podcast here: https://upticknewswire.com/featured-interview-ceo-alex-wasyl-of-nexien-biopharma-inc-otcqb-nxen/

About Nexien BioPharma Inc.

Nexien BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.

Current financial disclosure and Real-Time Level 2 quotes for Nexien BioPharma are available at www.otcmarkets.com or at www.NexienBioPharma.com.

Nexien BioPharma website: www.NEXIENBioPharma.com

Company Contact:

Mark Lubchenco

Director of Investor Relations

Nexien BioPharma Inc.

Tel. 1-303-495-7583

Email: mlubchenco@nexienbiopharma.com

Nexien Disclosure Notice

This press release may contain “forward-looking statements”, which are deemed to be any statements made by or on behalf ofNexien BioPharma thatare not statements of historical facts. These statements reflect current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this release, including the factors set forth in “Risk Factors” in our most recent Form 10-K filed with the Securities and Exchange Commission (SEC) and subsequent filings with the SEC. Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made.Nexien BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE: Uptick Newswire